{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T02:29:35Z","timestamp":1722220175372},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sanofi-Genzyme"},{"name":"Sanofi-Genzyme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>High concentrations of both phosphate and fibroblast growth factor 23 (FGF23) observed in chronic kidney disease (CKD) are associated with an increased risk of cardiovascular morbidity and mortality. Pulse wave velocity (PWV) is a surrogate marker for cardiovascular events and all-cause mortality. It is not known whether a reduction of FGF23 or phosphate alters cardiovascular risk. Sevelamer has shown to have the ability to reduce both phosphate and FGF23 concentrations. Furthermore, reduction of PWV is reported with sevelamer use as well, but it is unclear if this is mediated by decline of phosphate or FGF23. We investigated if sevelamer induced a decline in PWV and if this was associated with a reduction in FGF23.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In all, 24 normophosphataemic CKD Stage 3 patients started treatment with a fixed dose of sevelamer-carbonate (Renvela\u00ae) 2.4\u00a0g twice daily, with their usual diet for 8\u2009weeks in a single-arm study. PWV was measured and blood samples were obtained before, during and after washout of treatment with sevelamer. Vascular calcification was quantified using the Kauppila Index (KI). The primary outcome was the change of PWV from baseline to 8\u00a0weeks of treatment and the secondary endpoint was the difference of FGF23 following treatment with sevelamer. One of the linear mixed models was used to analyse the association between treatment and outcome. Mediation analysis was performed as a sensitivity analysis. The study was registered in the Dutch trial register (http:\/\/www.trialregister.nl: NTR2383).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 18 patients completed 8\u2009weeks of treatment with sevelamer and were analysed. Overall, treatment with sevelamer did not induce a significant reduction of PWV (\u03b2 = \u22120.36, P = 0.12). However, in patients with less vascular calcification (lower KI score), there was a statistically significant reduction of PWV, adjusted for mean arterial pressure, after treatment (\u03b2 = 0.63, P = 0.02). Addition of FGF23 to the model did not alter this association. Mediation analysis yielded similar results. FGF23 did not decrease during treatment with sevelamer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this short-term pilot study in normophosphataemic CKD patients, treatment with sevelamer did not improve PWV. In subgroup analysis, however, PWV improved in patients with no or limited abdominal aorta calcifications. This was not associated with a decline of FGF23.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfz027","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T20:21:59Z","timestamp":1550866919000},"page":"678-685","source":"Crossref","is-referenced-by-count":12,"title":["Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3"],"prefix":"10.1093","volume":"12","author":[{"given":"Annet","family":"Bouma-de Krijger","sequence":"first","affiliation":[{"name":"Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans J","family":"van Ittersum","sequence":"additional","affiliation":[{"name":"Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences Institute (ACS), O2 | Building for Human Life Sciences, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiny","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter M","family":"ter Wee","sequence":"additional","affiliation":[{"name":"Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G","family":"Vervloet","sequence":"additional","affiliation":[{"name":"Department of Nephrology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences Institute (ACS), O2 | Building for Human Life Sciences, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"2019093012015531100_sfz027-B1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2019093012015531100_sfz027-B2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"2019093012015531100_sfz027-B3","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2019093012015531100_sfz027-B4","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"2019093012015531100_sfz027-B5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2019093012015531100_sfz027-B6","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"2019093012015531100_sfz027-B7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2016.06.181","article-title":"Serum phosphorus is related to left ventricular remodeling independent of renal function in hospitalized patients with chronic kidney disease","volume":"221","author":"Zou","year":"2016","journal-title":"Int J Cardiol"},{"key":"2019093012015531100_sfz027-B8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00467-011-1822-0","article-title":"Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients","volume":"26","author":"Srivaths","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2019093012015531100_sfz027-B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ki.2010.194","article-title":"FGF-23 and vascular dysfunction in patients with Stage 3 and 4 chronic kidney disease","volume":"78","author":"Yilmaz","year":"2010","journal-title":"Kidney Int"},{"key":"2019093012015531100_sfz027-B10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"key":"2019093012015531100_sfz027-B11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.HYP.33.5.1111","article-title":"Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients","volume":"33","author":"Blacher","year":"1999","journal-title":"Hypertension"},{"key":"2019093012015531100_sfz027-B12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2007.07.012","article-title":"Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD","volume":"50","author":"Zoungas","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2019093012015531100_sfz027-B13","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1046\/j.1523-1755.2003.00932.x","article-title":"Aortic pulse wave velocity index and mortality in end-stage renal disease","volume":"63","author":"Blacher","year":"2003","journal-title":"Kidney Int"},{"key":"2019093012015531100_sfz027-B14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1681\/ASN.2013121355","article-title":"Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD","volume":"26","author":"Tripepi","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2019093012015531100_sfz027-B15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2019093012015531100_sfz027-B16","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1074\/jbc.M207872200","article-title":"Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production","volume":"278","author":"Saito","year":"2003","journal-title":"J Biol Chem"},{"key":"2019093012015531100_sfz027-B17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"2019093012015531100_sfz027-B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/08037051.2011.617045","article-title":"Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure","volume":"21","author":"Figueiredo","year":"2012","journal-title":"Blood Press"},{"key":"2019093012015531100_sfz027-B19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s000180050038","article-title":"Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases","volume":"57","author":"Nagai","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"2019093012015531100_sfz027-B20","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability","volume":"307","author":"Silswal","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2019093012015531100_sfz027-B21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.2009.246","article-title":"A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease","volume":"76","author":"Isakova","year":"2009","journal-title":"Kidney Int"},{"key":"2019093012015531100_sfz027-B22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019093012015531100_sfz027-B23","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2019093012015531100_sfz027-B24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease","volume":"7","author":"Vlassara","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019093012015531100_sfz027-B25","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0140-6736(15)60325-7","article-title":"Phosphate as a cardiovascular risk factor: effects on vascular and endothelial function","volume":"385","author":"Stevens","year":"2015","journal-title":"Lancet"},{"key":"2019093012015531100_sfz027-B26","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1681\/ASN.2008101106","article-title":"Dietary phosphorus acutely impairs endothelial function","volume":"20","author":"Shuto","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2019093012015531100_sfz027-B27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.2008.644","article-title":"The emerging role of phosphate in vascular calcification","volume":"75","author":"Giachelli","year":"2009","journal-title":"Kidney Int"},{"key":"2019093012015531100_sfz027-B28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ndt\/gfm660","article-title":"Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease","volume":"23","author":"Toussaint","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2019093012015531100_sfz027-B29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/acb.2009.009066","article-title":"Determination of fibroblast growth factor 23","volume":"46","author":"Heijboer","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"2019093012015531100_sfz027-B30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2019093012015531100_sfz027-B31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9150(97)00106-8","article-title":"New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study","volume":"132","author":"Kauppila","year":"1997","journal-title":"Atherosclerosis"},{"key":"2019093012015531100_sfz027-B32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5414\/CN107398","article-title":"Vascular stiffness in incident peritoneal dialysis patients over time","volume":"78","author":"Tang","year":"2012","journal-title":"Clin Nephrol"},{"key":"2019093012015531100_sfz027-B33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3 CKD","volume":"24","author":"Chue","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2019093012015531100_sfz027-B34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/ndt\/gfh656","article-title":"New strategy to attenuate pulse wave velocity in haemodialysis patients","volume":"20","author":"Takenaka","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2019093012015531100_sfz027-B35","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1111\/j.1542-4758.2007.00224.x","article-title":"Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study","volume":"11","author":"Othmane","year":"2007","journal-title":"Hemodial Int"},{"key":"2019093012015531100_sfz027-B36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4103\/0971-4065.103907","article-title":"The effect of L-arginine on arterial stiffness and oxidative stress in chronic kidney disease","volume":"22","author":"Annavarajula","year":"2012","journal-title":"Indian J Nephrol"},{"key":"2019093012015531100_sfz027-B37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijcard.2007.04.057","article-title":"Short-term treatment with L-arginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals","volume":"126","author":"Siasos","year":"2008","journal-title":"Int J Cardiol"},{"key":"2019093012015531100_sfz027-B38","doi-asserted-by":"crossref","first-page":"351059","DOI":"10.1155\/2015\/351059","article-title":"Effect of simvastatin on arterial stiffness in patients with statin myalgia","volume":"2015","author":"Ballard","year":"2015","journal-title":"Adv Prev Med"},{"key":"2019093012015531100_sfz027-B39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2019093012015531100_sfz027-B40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"2019093012015531100_sfz027-B41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000353569","article-title":"Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease","volume":"38","author":"Seifert","year":"2013","journal-title":"Am J Nephrol"},{"key":"2019093012015531100_sfz027-B42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ki.2013.110","article-title":"Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure","volume":"84","author":"Maizel","year":"2013","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/12\/5\/678\/30087991\/sfz027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T04:02:41Z","timestamp":1569902561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/12\/5\/678\/5419288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3,25]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz027","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,3,25]]}}}